CY1117559T1 - Ενωση ινδολιου και φαρμακευτικη χρηση αυτου - Google Patents

Ενωση ινδολιου και φαρμακευτικη χρηση αυτου

Info

Publication number
CY1117559T1
CY1117559T1 CY20161100462T CY161100462T CY1117559T1 CY 1117559 T1 CY1117559 T1 CY 1117559T1 CY 20161100462 T CY20161100462 T CY 20161100462T CY 161100462 T CY161100462 T CY 161100462T CY 1117559 T1 CY1117559 T1 CY 1117559T1
Authority
CY
Cyprus
Prior art keywords
indolium
union
pharmaceutical use
diseases
prophylaxis
Prior art date
Application number
CY20161100462T
Other languages
Greek (el)
English (en)
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Michihide Maekawa
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of CY1117559T1 publication Critical patent/CY1117559T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20161100462T 2009-11-25 2016-05-26 Ενωση ινδολιου και φαρμακευτικη χρηση αυτου CY1117559T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
EP10833248.7A EP2505586B1 (en) 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CY1117559T1 true CY1117559T1 (el) 2017-04-26

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100462T CY1117559T1 (el) 2009-11-25 2016-05-26 Ενωση ινδολιου και φαρμακευτικη χρηση αυτου

Country Status (31)

Country Link
US (6) US8299070B2 (cg-RX-API-DMAC7.html)
EP (3) EP2505586B1 (cg-RX-API-DMAC7.html)
JP (6) JP5734628B2 (cg-RX-API-DMAC7.html)
KR (1) KR101766502B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712624B (cg-RX-API-DMAC7.html)
AR (1) AR079164A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010323579C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012012529B1 (cg-RX-API-DMAC7.html)
CA (1) CA2781660C (cg-RX-API-DMAC7.html)
CL (1) CL2012001328A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541645A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117559T1 (cg-RX-API-DMAC7.html)
DK (1) DK2505586T3 (cg-RX-API-DMAC7.html)
ES (1) ES2572935T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160579T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028016T2 (cg-RX-API-DMAC7.html)
IL (1) IL220009A (cg-RX-API-DMAC7.html)
ME (1) ME02447B (cg-RX-API-DMAC7.html)
MX (1) MX2012006017A (cg-RX-API-DMAC7.html)
MY (1) MY161095A (cg-RX-API-DMAC7.html)
NZ (1) NZ600840A (cg-RX-API-DMAC7.html)
PE (1) PE20121358A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501021A1 (cg-RX-API-DMAC7.html)
PL (1) PL2505586T3 (cg-RX-API-DMAC7.html)
PT (1) PT2505586E (cg-RX-API-DMAC7.html)
RS (1) RS54910B1 (cg-RX-API-DMAC7.html)
RU (1) RU2556216C2 (cg-RX-API-DMAC7.html)
SI (1) SI2505586T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600258B (cg-RX-API-DMAC7.html)
TW (1) TWI491591B (cg-RX-API-DMAC7.html)
WO (1) WO2011065402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼcガンマ2及び耐性に関連した変異
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
CN112118843B (zh) * 2018-05-25 2023-09-29 日本烟草产业株式会社 使用吲哚化合物治疗疼痛或间质性膀胱炎的方法
JP7322007B2 (ja) * 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
JP7407705B2 (ja) * 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
IL293831B2 (en) 2019-12-20 2024-02-01 Pfizer Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240132477A1 (en) * 2020-12-15 2024-04-25 Pfizer Inc. Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
KR20250166329A (ko) * 2023-04-13 2025-11-27 다나틀라스 파마슈티컬즈 씨오., 엘티디. 티아디아졸론 유도체 및 이의 조성물과 응용

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005026175A1 (en) * 2003-09-08 2005-03-24 Aventis Pharmaceuticals Inc. Thienopyrazoles
EP1880993A4 (en) * 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd NITROGENIC HETEROCYCLIC COMPOUND
EP1968580A2 (en) 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
CA2781660C (en) 2018-06-26
PE20121358A1 (es) 2012-10-23
ME02447B (me) 2016-09-20
US20130116240A1 (en) 2013-05-09
ES2572935T3 (es) 2016-06-03
JP2021091718A (ja) 2021-06-17
CN102712624A (zh) 2012-10-03
IL220009A0 (en) 2012-07-31
CO6541645A2 (es) 2012-10-16
NZ600840A (en) 2014-01-31
HUE028016T2 (en) 2016-11-28
SMT201600258B (it) 2016-08-31
TW201124378A (en) 2011-07-16
JP2015172051A (ja) 2015-10-01
AR079164A1 (es) 2011-12-28
US20180362506A1 (en) 2018-12-20
JP5734628B2 (ja) 2015-06-17
AU2010323579C1 (en) 2016-11-03
DK2505586T3 (en) 2016-05-30
PH12012501021A1 (en) 2013-01-14
CA2781660A1 (en) 2011-06-03
JP2017039761A (ja) 2017-02-23
KR101766502B1 (ko) 2017-08-08
EP3059234A1 (en) 2016-08-24
CL2012001328A1 (es) 2012-10-05
BR112012012529B1 (pt) 2021-10-26
RS54910B1 (sr) 2016-10-31
EP3766877A1 (en) 2021-01-20
MY161095A (en) 2017-04-14
RU2556216C2 (ru) 2015-07-10
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
JP2011132222A (ja) 2011-07-07
AU2010323579A1 (en) 2012-07-19
PT2505586E (pt) 2016-06-03
BR112012012529A2 (pt) 2016-05-03
EP2505586A4 (en) 2013-05-15
JP2018158935A (ja) 2018-10-11
PL2505586T3 (pl) 2016-12-30
EP2505586A1 (en) 2012-10-03
TWI491591B (zh) 2015-07-11
US20170267662A1 (en) 2017-09-21
US20110306599A1 (en) 2011-12-15
AU2010323579B2 (en) 2016-05-19
HRP20160579T1 (hr) 2016-07-29
EP2505586B1 (en) 2016-03-02
SI2505586T1 (sl) 2016-08-31
CN102712624B (zh) 2014-06-04
US8299070B2 (en) 2012-10-30
US20210284627A1 (en) 2021-09-16
HK1174025A1 (en) 2013-05-31
WO2011065402A1 (ja) 2011-06-03
RU2012126129A (ru) 2013-12-27
JP2020079276A (ja) 2020-05-28
US20200255408A1 (en) 2020-08-13
IL220009A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1117559T1 (el) Ενωση ινδολιου και φαρμακευτικη χρηση αυτου
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1121631T1 (el) Ενωση πυραζολης και φαρμακευτικη χρηση εξ αυτης
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CR20160035A (es) Inhibidores de bromodominios
EA030189B8 (ru) Аналоги 2'-хлоронуклеозидов для инфекции вгс
CY1118340T1 (el) Αναστολεις κινασης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1118747T1 (el) Ενωση σπειρο-δακτυλιου που περιεχει αζωτο και ιατρικη χρηση αυτης
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
MX382699B (es) Compuestos macrocíclicos como inhibidores de trk cinasa.
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EP2581372A4 (en) CYANOCHINOLINDERIVATE
EP2875024A4 (en) HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
EP2642993A4 (en) COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF OR PHARMACEUTICALIZED SALT OF ROTIGOTINE OR ITS DERIVATIVES
EA201591024A1 (ru) Димерные соединения
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
DOP2016000266A (es) CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS